William Deraedt

Oncology R&D
Beerse, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial.

Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial.

Journal: Journal of patient-reported outcomes

Published: July 23, 2025

Real-World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1-3 Prior Lines of Therapy: Optum Database.

Real-World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1-3 Prior Lines of Therapy: Optum Database.

Journal: Cancer medicine

Published: April 25, 2025

CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma.

CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma.

Journal: The New England journal of medicine

Published: February 12, 2025

Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare Database.

Real-World Treatment Patterns and Outcomes in Patients With Lenalidomide-Refractory Multiple Myeloma With 1 to 3 Prior Lines: SEER-Medicare Database.

Journal: Clinical lymphoma, myeloma & leukemia

Published: October 20, 2024

Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.

Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.

Journal: The Lancet. Haematology

Published: May 08, 2024

Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials.

Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 02, 2024

Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database.

Real-world treatment patterns and outcomes in relapsed/refractory multiple myeloma (1-3 prior lines): Flatiron database.

Journal: Blood advances

Published: January 12, 2024

Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.

Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: March 21, 2023

Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.

Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.

Journal: Current medical research and opinion

Published: October 22, 2022

Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice.

Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice.

Journal: HemaSphere

Published: July 06, 2022

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.

Journal: Blood

Published: June 23, 2022

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 06, 2022

Showing 1-12 of 29

Last Updated: 09/26/2026